Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection

← catalyst calendar

NCT02932150 · readout ≤ 42 d

Sponsored by Gilead Sciences (industry) · GILD — their whole pipeline →.

Phase

Phase 2

Status

Active, not recruiting

Study type

Interventional

Design

Randomized · Double · Treatment

Enrollment

150estimated

Sites

Countries

Belgium, Hong Kong, India +5

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

Nov 2016

actual

When the study began enrolling

Primary completion

Sep 2026

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Oct 2029

estimated

The whole study's end, after follow-up

First posted

2016-10-13

estimated

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-06-18

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Chronic Hepatitis B

Interventions

Drug: TAF
Drug: Placebo

Primary outcomes

what the primary-completion date above is the date OF

Incidence of Treatment-Emergent Serious Adverse Events (SAEs) at Week 24

measured Week 24

Incidence of Treatment-Emergent Adverse Events (AEs) at Week 24

measured Week 24

Percentage of participants with plasma HBV DNA < 20 IU/mL at Week 24

measured Week 24

PK Parameter: AUCtau of TAF for participants from Cohort 2 Part A

measured Predose, 15 minutes, 30 minutes, 1, 1.5, 2, 3, 4, 5, and 8 hours postdose at Week 4 or 8 or 12

Permalink · GILD's whole pipeline · Catalyst calendar · Every registered study · What changed